Cargando…
Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
Cardiotoxicity is one of the major side effects of anti-cancer therapy affecting the overall prognosis of patients and possibly leading to the discontinuation of chemotherapy. Traditional cardiovascular tests such as electrocardiography and transthoracic echocardiography have limited sensitivity and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696384/ https://www.ncbi.nlm.nih.gov/pubmed/36354771 http://dx.doi.org/10.3390/jcdd9110372 |
_version_ | 1784838304365019136 |
---|---|
author | Zhang, Xinxin Sun, Yuxi Zhang, Yanli Fang, Fengqi Liu, Jiwei Xia, Yunlong Liu, Ying |
author_facet | Zhang, Xinxin Sun, Yuxi Zhang, Yanli Fang, Fengqi Liu, Jiwei Xia, Yunlong Liu, Ying |
author_sort | Zhang, Xinxin |
collection | PubMed |
description | Cardiotoxicity is one of the major side effects of anti-cancer therapy affecting the overall prognosis of patients and possibly leading to the discontinuation of chemotherapy. Traditional cardiovascular tests such as electrocardiography and transthoracic echocardiography have limited sensitivity and specificity for the early detection of myocardial injury. Cardiovascular imaging generally detects cancer therapy-related cardiac dysfunction (CTRCD) at advanced stages, whereas biomarkers are inexpensive, easily detected, reproducible, and capable of detecting even minimal cardiomyocyte damage or mild hemodynamic fluctuations. The presence of circulating cardiac biomarkers has been investigated as early indicators of cardiotoxicity and predictors of subsequent CTRCD. Currently, the most frequently used cardiac biomarkers are cardiac troponin (cTn) and natriuretic peptides (NPs). This review presents the evidence gathered so far regarding the usefulness and limitations of cardiac biomarkers in the field of cardio-oncology. |
format | Online Article Text |
id | pubmed-9696384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96963842022-11-26 Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity Zhang, Xinxin Sun, Yuxi Zhang, Yanli Fang, Fengqi Liu, Jiwei Xia, Yunlong Liu, Ying J Cardiovasc Dev Dis Review Cardiotoxicity is one of the major side effects of anti-cancer therapy affecting the overall prognosis of patients and possibly leading to the discontinuation of chemotherapy. Traditional cardiovascular tests such as electrocardiography and transthoracic echocardiography have limited sensitivity and specificity for the early detection of myocardial injury. Cardiovascular imaging generally detects cancer therapy-related cardiac dysfunction (CTRCD) at advanced stages, whereas biomarkers are inexpensive, easily detected, reproducible, and capable of detecting even minimal cardiomyocyte damage or mild hemodynamic fluctuations. The presence of circulating cardiac biomarkers has been investigated as early indicators of cardiotoxicity and predictors of subsequent CTRCD. Currently, the most frequently used cardiac biomarkers are cardiac troponin (cTn) and natriuretic peptides (NPs). This review presents the evidence gathered so far regarding the usefulness and limitations of cardiac biomarkers in the field of cardio-oncology. MDPI 2022-10-29 /pmc/articles/PMC9696384/ /pubmed/36354771 http://dx.doi.org/10.3390/jcdd9110372 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zhang, Xinxin Sun, Yuxi Zhang, Yanli Fang, Fengqi Liu, Jiwei Xia, Yunlong Liu, Ying Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity |
title | Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity |
title_full | Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity |
title_fullStr | Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity |
title_full_unstemmed | Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity |
title_short | Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity |
title_sort | cardiac biomarkers for the detection and management of cancer therapy-related cardiovascular toxicity |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696384/ https://www.ncbi.nlm.nih.gov/pubmed/36354771 http://dx.doi.org/10.3390/jcdd9110372 |
work_keys_str_mv | AT zhangxinxin cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity AT sunyuxi cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity AT zhangyanli cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity AT fangfengqi cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity AT liujiwei cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity AT xiayunlong cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity AT liuying cardiacbiomarkersforthedetectionandmanagementofcancertherapyrelatedcardiovasculartoxicity |